Svetlana Sergeevna Solyanik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Svetlana Sergeevna Solyanik has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Sofiat Khasenovna Sizhazheva
Department of Public Health, Health Care and Preventive Medicine Kabardino-Balkarian State University named after H.M. Berbekov Nalchik, Russia
2 shared publications - Tamara Muratovna Khokonova
Department of Microbiology, Virology, and Immunology, Kabardino-Balkar Berbekov’s State University, 176 Chernishevskogo St., 360000 Nal’chik, Russia
2 shared publications - Dzhannet Anuarovna Elmurzaeva
Kabardino-Balkarian State University
1 shared publication - Dzhanneta Magometovna Urusbieva
Berbekov Kabardino-Balkarian State University
1 shared publication - Inara Aslanovna Khakuasheva
Berbekov Kabardino-Balkarian State University
1 shared publication - Marina Tembulatovna Nalchikova
Department of Infectious diseases Kabardino-Balkarian state University named after H.M. Berbekov Nalchik, Russia
1 shared publication
Latest Publications
- Open Access
- 8 May 2021
- Published by Universidad del Zulia in Revista de la Universidad del Zulia
- Vol. 12 (33) , 274-287
Analysis of hemodynamic parameters and quality of life in patients with chronic kidney disease and arterial hypertension
Purpose. The work is devoted to study the effects of antihypertensive, lipid-lowering and metabolic therapy in office and the average hemodynamic parameters, the parameters of central pressure in the aorta, vascular wall stiffness and quality of life in patients with CKD stage 3 in combination with arterial hypertension of 1-2 degrees, and without it. Materials and methods. Were examined patients with arterial hypertension of 1-2 degrees and CKD stage 3. Measured hemodynamic parameters with the help of a daily BP monitor “BPLab”. The quality of life of patients was assessed by the questionnaire MOS SF36. Results. The greatest changes in the indicators of central hemodynamics and vascular stiffness were noted in the group of patients with comorbidity. Conclusion. The combination of antihypertensive therapy (losartan and diltiazem) with meldonium and rosuvastatin significantly decreases indices of central and peripheral hemodynamics and vascular stiffness. Add meldonium part of therapy significantly improves the quality of life of patients.
- 8 May 2021
- Published by Universidad del Zulia in Revista de la Universidad del Zulia
- Vol. 12 (33) , 274-287
Open AccessAnalysis of hemodynamic parameters and quality of life in patients with chronic kidney disease and arterial hypertension
Purpose. The work is devoted to study the effects of antihypertensive, lipid-lowering and metabolic therapy in office and the average hemodynamic parameters, the parameters of central pressure in the aorta, vascular wall stiffness and quality of life in patients with CKD stage 3 in combination with arterial hypertension of 1-2 degrees, and without it. Materials and methods. Were examined patients with arterial hypertension of 1-2 degrees and CKD stage 3. Measured hemodynamic parameters with the help of a daily BP monitor “BPLab”. The quality of life of patients was assessed by the questionnaire MOS SF36. Results. The greatest changes in the indicators of central hemodynamics and vascular stiffness were noted in the group of patients with comorbidity. Conclusion. The combination of antihypertensive therapy (losartan and diltiazem) with meldonium and rosuvastatin significantly decreases indices of central and peripheral hemodynamics and vascular stiffness. Add meldonium part of therapy significantly improves the quality of life of patients.
- 20 December 2020
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 12,p. 46-56
Dynamics of central hemodynamic parameters and cytokine levels in patients with chronic kidney disease and arterial hypertension during combination therapy
The effect of antihypertensive and hypolipidemic therapy with the use of a fixed combination of amlodipine, lisinopril and rosuvastatin on the parameters of cytokines (the level of the proinflammatory cytokine - interleukin-1β, anti-inflammatory cytokine - interleukin-10, ligand CD40 (CD40L)), central aortic pressure, arterial stiffness and the value of albuminuria in patients with stage 3 chronic kidney disease, both in combination with arterial hypertension (AH) of 1-2 degrees, and without it, and in patients with coronary artery disease in combination with AH. The results of the study allow to conclude that the proposed antihypertensive and hypolipidemic therapy significantly reduces the parameters of central hemodynamics and vascular stiffness, the levels of microalbuminuria (MAU) and blood creatinine in patients with stage 3 chronic kidney disease in combination with AH of 1-2 degrees, and significantly increases the values IL-10 in patients with hypertension and CKD.
- 20 December 2020
- Published by PANORAMA Publishing House in Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
- No. 12,p. 46-56
Dynamics of central hemodynamic parameters and cytokine levels in patients with chronic kidney disease and arterial hypertension during combination therapy
The effect of antihypertensive and hypolipidemic therapy with the use of a fixed combination of amlodipine, lisinopril and rosuvastatin on the parameters of cytokines (the level of the proinflammatory cytokine - interleukin-1β, anti-inflammatory cytokine - interleukin-10, ligand CD40 (CD40L)), central aortic pressure, arterial stiffness and the value of albuminuria in patients with stage 3 chronic kidney disease, both in combination with arterial hypertension (AH) of 1-2 degrees, and without it, and in patients with coronary artery disease in combination with AH. The results of the study allow to conclude that the proposed antihypertensive and hypolipidemic therapy significantly reduces the parameters of central hemodynamics and vascular stiffness, the levels of microalbuminuria (MAU) and blood creatinine in patients with stage 3 chronic kidney disease in combination with AH of 1-2 degrees, and significantly increases the values IL-10 in patients with hypertension and CKD.